MDNAF News and Press, Mandatum Pankki Oyj From 11/02/20

TORONTO and HOUSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will prese...

-- Monotherapy and combination studies continue to demonstrate best - in - class potential of MDNA11 -- B ispecific IL-2/IL-13 Superkine demonstrates the potential to treat immunologically “cold” tumors TORONTO and HOUSTON, Oct...

--  Amongst an all-comer population, a single treatment with MDNA55 resulted in at least 100% increase in both 12 month progression free survival (PFS-12 of 27% versus 2 to 10% ) and 2-year survival (OS-24 of 20% vs 5 to10% ...

TORONTO and HOUSTON, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two abstracts at the EORTC-NCI-AACR ("ENA") Virtual Scientific P...

- After consultation with the FDA, the company can conduct a hybrid registration trial that allows for the use of matched external controls for two-thirds of control arm - - The design sets a new precedent for GBM clinical trials, allowing robust OS analysis and significantly red...

TORONTO and HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will pres...

TORONTO and HOUSTON, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that the Company’s common shares have been approved for listing on The Nasdaq Capit...

Medicenna Therapeutics ( OTCQB:MDNAF ) : Q1 GAAP EPS of -C$0.05. More news on: Medicenna Therapeutics Corp., Earnings news and commentary, Consumer stocks news, , Read more ...

 - Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55  - EOP2 meeting scheduled for 29 th September, 2020 with FDA input expected in calendar Q4 2020    - Presented ne...

Medicenna Therapeutics Corp. [TSX:MDNA] ( OTCQB:MDNAF ) is a Toronto-based clinical-stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines. Superkines can be engineered as short or long-acting therapeutics or fused with cell-killing protei...